Latest Breaking News On - Intraocular inflammation - Page 1 : comparemela.com

Regenxbio Stock: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips (RGNX)

Regenxbio Stock: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips (RGNX)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

DelawareUnited statesUniversity of pennsylvaniaDistrict courtAbbvie incDigital eyeDuchenne muscular dystrophyIntraocular inflammationConjunctival hemorrhageIntraocular pressure increasedConjunctival hyperemiaDiabetic retinopathy severity scaleBiologics license application

Long-Term Outcomes of Pegcetacoplan for GA Show Promise

Results of the 30-month data cut of the 3-year GALE open-label extension trial of pegcetacoplan for geographic atrophy showed that the drug produced clinically meaningful reductions in lesion growth.

WashingtonUnited statesSeattleCaliforniaAmericanRoger goldbergAmerican society of retina specialistsBay area retina associates in pleasantonApellis pharmaceuticalsAmerican societyBay area retina associatesRetina specialistsPresented julyExudative age related macular degenerationXudative armdPhakic iol

Complications From Geographic Atrophy Drug Fuel Questions

An extension study found no cases of occlusive retinal vasculitis after 23,000 injections of pegcetacoplan, but a panel received more reports of the complication and dealt with conflicts of interest.

OaklandCaliforniaUnited statesBostonMassachusettsAmericanIveric bioAndre witkinJill blimSoraya rofaghaPeter kaiserNathan steinleLuis obispoGenentech rocheDrug administrationRegeneron pharmaceuticals

Retina Group Warns on Complications From New GA Drug

The American Society of Retina Specialists has reported six cases of vasculitis not seen in clinical trials.

MassachusettsUnited statesBostonAmericansAmericanDemetriosg vavvasRetina service at harvard medical schoolDrug administrationOcular regenerative medical institute at massachusetts eyeAmerican society of retina specialistsApellis pharmaceuticalsAmerican societyRetina specialistsMedscape medical newsRetina serviceHarvard medical school

Significant Decreases in Ocular Blood Flow Observed with Brolucizumab, Aflibercept Injections

Intravitreal brolucizumab and aflibercept in eyes with nAMD were each linked to a significant decrease in the ocular blood flow 30 minutes after injection.

Marc schulte pexelsActa ophthalmolMasatoshi harutaClin ophthalmolKurume university school of medicineKurume university hospitalDepartment of ophthalmologyKurume university schoolNeovascular age related macularIntraocular inflammationRetinal vasculitisVascular occlusion